Two machine learning-derived nomogram for predicting the occurrence and severity of acute graft-versus-host disease: a retrospective study based on serum biomarkers

被引:0
|
作者
He, Qiang [1 ]
Li, Xin [2 ]
Fang, Yuan [3 ]
Kong, Fansheng [3 ]
Yu, Zhe [2 ]
Xie, Linna [1 ]
机构
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[2] Gen Hosp Jinan Mil, Dept Hematol, Jinan, Shandong, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Hematol, Jinan, Shandong, Peoples R China
关键词
acute graft-versus-host disease; diagnosis; machine learning; nomogram; prediction model; T-CELLS; ACUTE GVHD; EXPRESSION; TRANSPLANTATION;
D O I
10.3389/fgene.2024.1421980
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Acute graft-versus-host disease (aGVHD) is a common complication after allogeneic hematopoietic cell transplantation (allo-HSCT), with high morbidity and mortality. Although glucocorticoids are the standard treatment, only half of patients achieve complete remission. Thus, there is an urgent need to screen biomarkers for the diagnosis of aGVHD to assist in the identification of individuals at risk of aGVHD. This study was to construct prediction models for the occurrence and severity of aGVHD using two machine learning algorithms based on serum biochemical data. Methods Clinical data of 120 patients with hematological diseases who received allo-HSCT were retrospectively analyzed. Seventy-six patients developed aGVHD, including 56 grade I/II and 20 grade III/IV. First, 15 serum biochemical indicators were considered as potential risk factors, and the differences in the levels of indicators between non-aGVHD and aGVHD were observed, followed by evaluation of the diagnostic property. Subsequently, to develop the prediction models for the occurrence and severity of aGVHD, LASSO and random forest (RF) analyses were performed with experimental indicators. Finally, Venn diagram analysis was utilized to obtain shared biomarkers in the two algorithms to construct the nomogram. The model performance was measured by calibration curves. Internal and external validations were performed based on risk score models and ROC curve analyses. Results Total 12 of 15 indicators exhibited significant differences between the aGVHD and non-aGVHD groups, with AUC values > 0.75. In machine learning analysis, eight features (LAG-3, TLR-2, PD-L1, IP-10, elafin, REG-3 alpha, ST2, TIM3) and seven variables (LAG-3, TLR-2, PD-1, Flt_3, IL-9, elafin, TIM3) were selected to distinguish aGVHD vs. non-aGVHD as well as grade I/II vs. III/IV, respectively. Further, the corresponding nomogram models were established and calibration curves showed that prediction was in good agreement with the actual probability. Biomarker-based risk score model was constructed, which obtained AUC value >0.89 in internal and external datasets. Conclusion Clinical variables screened through learning algorithm can predict the risk and severity of aGVHD. Our findings may help clinicians develop more personalized and reasonable management strategies.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Biomarkers associated with occurrence and severity of graft-versus-host disease
    Ahmed, S.
    Donze, O.
    Holler, E.
    Wang, X. N.
    Dickinson, A. M.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S131 - S132
  • [2] A machine learning approach to acute graft-versus-host disease grading
    Bayraktar, E.
    Leserer, S.
    Yi, J. -H.
    Bogdanov, R.
    Alashkar, F.
    Beelen, D.
    Turki, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 59 - 59
  • [3] A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
    Levine, John E.
    Braun, Thomas M.
    Harris, Andrew C.
    Holler, Ernst
    Taylor, Austin
    Miller, Holly
    Magenau, John
    Weisdorf, Daniel J.
    Ho, Vincent T.
    Bolanos-Meade, Javier
    Alousi, Amin M.
    Ferrara, James L. M.
    LANCET HAEMATOLOGY, 2015, 2 (01): : E21 - E29
  • [4] Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
    Robin, Marie
    Porcher, Raphael
    Michonneau, David
    Taurines, Laetitia
    de Fontbrune, Flore Sicre
    Xhaard, Alienor
    Oriano, Bastien
    Del Galy, Aurelien Sutra
    de Latour, Regis Peffault
    Socie, Gerard
    Schlageter, Marie-Helene
    BLOOD ADVANCES, 2022, 6 (16) : 4763 - 4772
  • [5] A panel of mass spectrometry based serum protein tests for predicting Graft-versus-Host Disease (GvHD) and its severity
    Koldehoff, M.
    Roder, J.
    Hoffmann, A. C.
    Roder, H.
    Oncology Research and Treatment, 2015, 38 : 72 - 73
  • [6] A panel of mass spectrometry based serum protein tests for predicting graft-versus-host disease (GvHD) and its severity
    Roder, Heinrich
    Hoffmann, Andreas-Claudius
    Roder, Joanna
    Koldehoff, Michael
    CANCER RESEARCH, 2015, 75
  • [7] Acute Graft-Versus-Host Disease After Orthotopic Liver Transplantation: Predicting This Rare Complication Using Machine Learning
    Cooper, Jason P.
    Perkins, James D.
    Warner, Paul R.
    Shingina, Alexandra
    Biggins, Scott W.
    Abkowitz, Janis L.
    Reyes, Jorge D.
    LIVER TRANSPLANTATION, 2022, 28 (03) : 407 - 421
  • [8] IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
    Rowlings, PA
    Przepiorka, D
    Klein, JP
    Gale, RP
    Passweg, JR
    HensleeDowney, PJ
    Cahn, JY
    Calderwood, S
    Gratwohl, A
    Socie, G
    Abecasis, MM
    Sobocinski, KA
    Zhang, MJ
    Horowitz, MM
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (04) : 855 - 864
  • [9] The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
    Yang, Wenli
    Zhu, Guanghua
    Qin, Maoquan
    Li, Zhigang
    Wang, Bin
    Yang, Jun
    Wang, Tianyou
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 743 - 752
  • [10] Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study
    Liu, Jiapei
    Fan, Zhiping
    Xu, Na
    Ye, Jieyu
    Chen, Yanqiu
    Shao, Ruoyang
    Sun, Yiming
    Wu, Qiaoyuan
    Liu, Qifa
    Jin, Hua
    ANNALS OF HEMATOLOGY, 2023, 102 (10) : 2865 - 2877